Key result
This review discusses the molecular biology, electrophysiologic mechanisms, and pharmacologic agents associated with congenital and acquired long QT syndrome and torsade de pointes.
Population
Patients with congenital or acquired long QT syndrome, and anthopleurin-A canine models (surrogate for LQT3)
Design
Review
Authors
Loading...
Supports risk-benefit assessment before QT-prolonging prescriptions; leaves open novel mechanistic targets for future therapies.
This review highlights the molecular, cellular, and electrophysiologic mechanisms underlying torsade de pointes in long QT syndrome, emphasizing the importance of risk-benefit assessment before prescribing QT-prolonging drugs.
El‐Sherif et al. (2003) conducted a review in Torsade de pointes and long QT syndrome. This review discusses the molecular biology, electrophysiologic mechanisms, and pharmacologic agents associated with congenital and acquired long QT syndrome and torsade de pointes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: